Critical interactions between darunavir (TMC114), lopinavir, Viagra, and oral contraceptives
7 October 2006. Related: Conference reports, PK and drug interactions.
PK and drug interactions
Relationship between nevirapine concentrations and virological failure in a clinical setting
11 June 2006. Related: Conference reports, PK and drug interactions.
Summary of drug interaction studies
11 June 2006. Related: Conference reports, PK and drug interactions.
Effects of ketoconazole and rifampin on TMC278
10 June 2006. Related: Conference reports, PK and drug interactions.
Brecanavir interaction study with ritonavir and atazanavir
10 June 2006. Related: Conference reports, PK and drug interactions.
Dosing rifabutin and lopinavir/r sub-optimal rifabutin levels reported in five patients dosed according to current guidelines
12 May 2006. Related: Conference reports, PK and drug interactions, TB coinfection.
Pharmacology and drug interaction studies in adults: summary table from CROI, ICAAC and EACS conferences
12 April 2006. Related: Conference reports, PK and drug interactions.
Nelfinavir reduces pravastatin AUC by 46% in HIV negative volunteers
11 April 2006. Related: PK and drug interactions.
Overview of pharmacology studies
14 September 2005. Related: Conference reports, PK and drug interactions.
Levels of efavirenz 10-fold above minimum target level despite coadministration with rifampicin
15 June 2005. Related: Conference reports, PK and drug interactions, Side effects.
Summary of drug-drug interaction studies
15 June 2005. Related: Conference reports, PK and drug interactions.
Atazanavir boosts intracellular saquinavir levels: data on important new dual-boosted regimen
29 March 2005. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Interactions between African herbal medicines and ARVs
29 March 2005. Related: PK and drug interactions.
Atorvastatin requires dose reduction with tipranavir/r
29 January 2005. Related: Conference reports, PK and drug interactions.
Fluconazole increases nevirapine levels and risk of serious hepatotoxicity
6 September 2004. Related: Conference reports, PK and drug interactions.
Efavirenz interaction with rifampin may not require dose adjustment in patients with low body weight
6 September 2004. Related: Conference reports, PK and drug interactions.
Tipranavir significantly lowers doses of saquinavir, amprenavir and lopinavir/r
6 September 2004. Related: Conference reports, PK and drug interactions.
Non-prescription simvastatin in the UK: contraindicated with many HIV medications
29 July 2004. Related: PK and drug interactions.
Label changes for indinavir warn of several interactions including atazanavir and PDE5 inhibitors
29 July 2004. Related: PK and drug interactions.
5th International Workshop on Clinical Pharmacology of HIV Therapy, 1-3 April 2004, Rome, Italy
2 May 2004. Related: Conference reports, PK and drug interactions.
Large reductions in plasma PK levels of saquinavir, amprenavir and lopinavir/r levels when given with tipranavir/ritonavir
2 May 2004. Related: Conference reports, PK and drug interactions.
Good generic drugs and good adherence in Rwanda
2 May 2004. Related: Conference reports, Treatment access, PK and drug interactions.
Steady state PK of nelfinavir and M8 in pregnancy
2 May 2004. Related: Conference reports, Pregnancy, PK and drug interactions, TB coinfection.
Higher nelfinavir concentrations improve response in children
2 May 2004. Related: Conference reports, Paediatric care, PK and drug interactions.
PK of once daily lopinavir/r in children
2 May 2004. Related: Conference reports, Paediatric care, PK and drug interactions.
Eating grapefruit triggers statin-related rhabdomyolysis
2 May 2004. Related: PK and drug interactions, Side effects.
Drug levels can persist for more than two weeks after stopping efavirenz
3 April 2004. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Race affects absorption and clearance of efavirenz
3 April 2004. Related: Conference reports, PK and drug interactions, Side effects.
Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination
3 April 2004. Related: Conference reports, PK and drug interactions.
Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome
3 April 2004. Related: Conference reports, PK and drug interactions.
Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T
3 April 2004. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
Interaction between amprenavir and lopinavir thwarts triple PI salvage
1 November 2003. Related: PK and drug interactions.
Vitamin C induces P4503A4 and reduces indinavir levels
1 November 2003. Related: PK and drug interactions.
Indinavir levels reduced by omeprazole
1 November 2003. Related: PK and drug interactions.
Boosted saquinavir PK in once-daily regimes
1 November 2003. Related: PK and drug interactions.
Tenofovir drug-drug interactions
1 November 2003. Related: PK and drug interactions.
Summary of other PK studies
1 November 2003. Related: PK and drug interactions.
Uridine as a potential treatment for NRTI related mitochondrial toxicity
1 September 2003. Related: Conference reports, PK and drug interactions, Side effects.
Pharmacology studies at the 2nd IAS conference
1 September 2003. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
4th International Workshop on Clinical Pharmacology of HIV Therapy, 27-29 March 2003, Cannes, France
1 May 2003. Related: Conference reports, PK and drug interactions.
Can low NVP plasma concentrations explain the results seen in the EFV and NVP containing arms of the NARVAL study?
1 May 2003. Related: Conference reports, PK and drug interactions.
Up to one third of patients receiving standard doses of NNRTIs may be being underdosed
1 May 2003. Related: Conference reports, PK and drug interactions.
Nelfinavir concentrations are significantly higher in HIV/HCV co-infected patients with cirrhosis
1 May 2003. Related: Conference reports, PK and drug interactions.
Less diarrhoea and bioequivalence with the new nelfinavir 625mg tablet
1 May 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions, Side effects.
The potential for probenecid to have a serious interaction with HIV-1 protease inhibitors
1 May 2003. Related: Conference reports, PK and drug interactions, Side effects.
PK studies reveal significant sex/gender differences
1 May 2003. Related: Conference reports, Women's health, PK and drug interactions.
Pregnancy-related PK studies
1 May 2003. Related: Conference reports, Pregnancy, PK and drug interactions.
New test to measure intracellular levels of nucleosides
1 May 2003. Related: Conference reports, PK and drug interactions.
Case studies for therapeutic drug monitoring (TDM)
1 May 2003. Related: Conference reports, PK and drug interactions.
Launch of guide to the use of drug level monitoring
1 May 2003. Related: Conference reports, PK and drug interactions.
Pharmacokinetic papers from 10th CROI
1 May 2003. Related: Conference reports, PK and drug interactions.
NIH/NIAID study of generic drugs shows results consistent with stringent manufacturing standards
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment access, PK and drug interactions.
Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected patients
1 April 2003. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
Pharmacokinetic evaluation of tenofovir and enteric-coated ddI
1 February 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Milk thistle can reduce levels of indinavir in the blood
13 November 2002. Related: PK and drug interactions.
US FDA announces important changes in amprenavir product labelling
13 October 2002. Related: Antiretrovirals, PK and drug interactions.
St John’s Wort interferes with chemotherapy, study shows
13 October 2002. Related: PK and drug interactions, Cancer and HIV.
Garlic can impede HIV medication
9 December 2001. Related: PK and drug interactions.
Caution needed with nelfinavir and some lipid-lowering drugs
9 December 2001. Related: PK and drug interactions.
Combinations of lopinavir/r and amprenavir in heavily treatment experienced patients
2 November 2001. Related: Conference reports, PK and drug interactions.
No significant drug interactions found between tenofovir DF and indinavir, lopinavir/r, lamivudine, or efavirenz
2 November 2001. Related: Conference reports, PK and drug interactions.
Ritonavir corrects drug interaction between efavirenz and saquinavir
2 November 2001. Related: Conference reports, PK and drug interactions.
Pharmacology at 1st IAS
1 September 2001. Related: Conference reports, PK and drug interactions.
Drug-drug interactions
1 September 2001. Related: Conference reports, PK and drug interactions.
A warning about milk thistle (silymarin) and drug interactions
30 July 2001. Related: PK and drug interactions.